» Articles » PMID: 33718405

Eosinophilic Granulomatosis With Polyangiitis: Dissecting the Pathophysiology

Overview
Specialty General Medicine
Date 2021 Mar 15
PMID 33718405
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare multisystemic disease classified both amongst hypereosinophilic disorders and ANCA-associated vasculitis. Vessel inflammation and eosinophilic proliferation are the hallmarks of the disease and main effectors of organ damage. Two distinct disease phenotypes have classically been described according to ANCA-status: the ANCA-negative subset with eosinophil-driven manifestation and the ANCA-positive one with vasculitic manifestations. An analogous dichotomization has also been backed by histological findings and a distinct genetic background. EGPA is typically consider a Th2-mediated disease and blood and tissue eosinophilia represent the cornerstone of diagnosis. Besides, ANCA are known for inducing endothelial injury and vascular inflammation by activating the circulating neutrophils. Thus, the pathogenesis of EGPA seems to be mediated by two coexisting mechanisms. However, the verbatim application of this strict dualism cannot always be translated into routine clinical practice. In the present review we describe the current knowledge on the eosinophilic and ANCA-mediated aspects of EGPA pathogenesis. Finally, we review the rationale of the currently proposed EGPA dichotomy and future research perspectives.

Citing Articles

Heterogeneity and individualized therapy for eosinophilic granulomatosis with polyangiitis.

Hua L, Xie M Ther Adv Respir Dis. 2025; 19:17534666251318615.

PMID: 39980304 PMC: 11843704. DOI: 10.1177/17534666251318615.


The diagnosis of eosinophilic granulomatosis with polyangiitis has been 'masked' by asthma: a case report.

Xie H, Zhang X, Zhang J, Liu M, Che X AME Case Rep. 2025; 9():31.

PMID: 39866258 PMC: 11760517. DOI: 10.21037/acr-24-79.


Prevalence and characteristics of bronchiectasis in ANCA-associated vasculitis: A systematic review and meta-analysis.

Gu Y, Zhang T, Zhu W, Han Y, Shi J Arch Rheumatol. 2024; 39(3):488-509.

PMID: 39507849 PMC: 11537674. DOI: 10.46497/ArchRheumatol.2024.10352.


Long-term efficacy of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis: a propensity score matching analysis in the multicenter REVEAL cohort study.

Shiomi M, Watanabe R, Matsuda S, Kotani T, Okazaki A, Masuda Y Front Immunol. 2024; 15:1457202.

PMID: 39416779 PMC: 11479934. DOI: 10.3389/fimmu.2024.1457202.


Efficacy and Safety of Mepolizumab in Patients With Eosinophilic Granulomatosis With Polyangiitis: A Single-Center Experience.

Abuzakouk M, Isse S, Wechsler M, Uzbeck M, Namas R, Ghorab O Cureus. 2024; 16(8):e68282.

PMID: 39350857 PMC: 11440447. DOI: 10.7759/cureus.68282.


References
1.
Zagai U, Dadfar E, Lundahl J, Venge P, Skold C . Eosinophil cationic protein stimulates TGF-beta1 release by human lung fibroblasts in vitro. Inflammation. 2007; 30(5):153-60. DOI: 10.1007/s10753-007-9032-4. View

2.
Jakiela B, Szczeklik W, Sokolowska B, Mastalerz L, Sanak M, Plutecka H . Intrinsic pathway of apoptosis in peripheral blood eosinophils of Churg-Strauss syndrome. Rheumatology (Oxford). 2009; 48(10):1202-7. DOI: 10.1093/rheumatology/kep209. View

3.
Cools J, DeAngelo D, Gotlib J, Stover E, Legare R, Cortes J . A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003; 348(13):1201-14. DOI: 10.1056/NEJMoa025217. View

4.
Yang D, Chen Q, Su S, Zhang P, Kurosaka K, Caspi R . Eosinophil-derived neurotoxin acts as an alarmin to activate the TLR2-MyD88 signal pathway in dendritic cells and enhances Th2 immune responses. J Exp Med. 2008; 205(1):79-90. PMC: 2234357. DOI: 10.1084/jem.20062027. View

5.
Shida H, Nakazawa D, Tateyama Y, Miyoshi A, Kusunoki Y, Hattanda F . The Presence of Anti-Lactoferrin Antibodies in a Subgroup of Eosinophilic Granulomatosis with Polyangiitis Patients and Their Possible Contribution to Enhancement of Neutrophil Extracellular Trap Formation. Front Immunol. 2017; 7:636. PMC: 5179553. DOI: 10.3389/fimmu.2016.00636. View